Novo’s Wegovy pill is planned to enter U.S. self-pay channels, Reuters says

Group 1 - Novo Nordisk's newly approved version of Wegovy is set to launch in U.S. self-pay channels in early January [1] - The company has agreed to sell starter doses of its weight-loss pills for $149 a month to U.S. Medicare and Medicaid patients, as well as cash-paying customers without insurance [1] - This initiative is part of a deal with the Trump administration and will serve as a test case for the cash-paying consumer market [1]